--- title: "A Look At Inventiva (ENXTPA:IVA) Valuation As New Leadership Team Prepares For Key Phase 3 Readout" type: "News" locale: "en" url: "https://longbridge.com/en/news/285005690.md" description: "Inventiva (ENXTPA:IVA) has appointed a new leadership team as it prepares for a key Phase 3 data readout. The share price is currently €4.31, reflecting a 6.55% year-to-date return but a 16.15% decline over the past 90 days. Despite a net loss of €354.138 million, the company has strong financial backing, ensuring a cash runway until September 2026. Analysts suggest a fair value of €10.00, indicating the stock is undervalued. However, concerns over losses and auditor flagged risks may challenge this narrative." datetime: "2026-05-03T22:08:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285005690.md) - [en](https://longbridge.com/en/news/285005690.md) - [zh-HK](https://longbridge.com/zh-HK/news/285005690.md) --- # A Look At Inventiva (ENXTPA:IVA) Valuation As New Leadership Team Prepares For Key Phase 3 Readout Inventiva (ENXTPA:IVA) reshaped its leadership team, appointing a new Chief Financial Officer, Chief Legal Officer, and Chief People Officer as it prepares for a key Phase 3 NATiV3 data readout later this year. See our latest analysis for Inventiva. The latest leadership reshuffle comes as the share price sits at €4.31, with a 6.55% year to date share price return but a 16.15% decline over 90 days. At the same time, the 1 year total shareholder return of 33.02% and 3 year total shareholder return of 79.58% suggest longer term holders have seen stronger momentum. If you are weighing Inventiva’s setup against other opportunities in the market, this is a good moment to widen the lens and check out 125 healthcare AI stocks With revenue of €6.761m against a net loss of €354.138m and the share price well below the €10.0004 analyst target, investors have to ask: is risk already reflected, or is the market quietly pricing in future growth? ## Most Popular Narrative: 56.9% Undervalued With the most followed fair value sitting at €10.00 against a last close of €4.31, the current market price sits well below that narrative anchor. > _Strong financial backing from dilutive and nondilutive financing operations, including a structured deal worth up to €348 million, ensures a cash runway sufficient to reach September 2026 with the second tranche. This financial strength can support sustained investment in commercialization, potentially affecting future earnings._ Read the complete narrative. Curious how that runway, the revenue ramp assumptions and future margin profile all connect to a single fair value number? The full narrative lays out the growth curve, embedded profitability swing and the earnings multiple used to arrive at that €10 mark, as well as how analyst disagreements shape the range around it. **Result: Fair Value of €10.00 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the thesis still leans heavily on lanifibranor and sits against a backdrop of sizeable losses and auditor flagged going concern risk, which could challenge that €10 narrative. Find out about the key risks to this Inventiva narrative. ## Next Steps With sentiment clearly split between concern over losses and optimism around potential rewards, it helps to look at the numbers yourself and decide quickly where you stand. Start with the 1 key reward and 4 important warning signs. ## Looking for more investment ideas? If Inventiva is on your radar, do not stop there. Widen your opportunity set with fresh stock ideas filtered by quality, value and risk. - Target cash generative businesses by scanning the solid balance sheet and fundamentals stocks screener (385 results) and see which companies pair financial strength with ongoing operations. - Hunt for potential value opportunities using the 245 high quality undervalued stocks to surface companies where the current price sits below fundamental estimates. - Prioritise resilience and steadier profiles through the 304 resilient stocks with low risk scores and focus on businesses with lower overall risk scores. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [IVA.US](https://longbridge.com/en/quote/IVA.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility](https://longbridge.com/en/news/286962960.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md) - [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)